1. Ishiguro, Takahiro, Yuji Sano, Shun-Ichiro Komatsu, Mika Kamata-Sakurai, Akihisa Kaneko, Yasuko Kinoshita,Hirotake Shiraiwa, et al. 2017. “An Anti-Glypican 3/CD3 Bispecific T Cell-Redirecting Antibody for Treatment of Solid Tumors.” Science Translational Medicine 9 (410). American Association for the Advancement of Science:eaal4291. doi:10.1126/scitranslmed.aal4291.
2.Akkermans O, Delloye-Bourgeois C, Peregrina C, Carrasquero-Ordaz M, Kokolaki
M, Berbeira-Santana M, Chavent M, Reynaud F, Raj R, Agirre J, Aksu M, White ES,
Lowe E, Ben Amar D, Zaballa S, Huo J, Pakos I, McCubbin PTN, Comoletti D,OwensRJ, Robinson CV, Castellani V, Del Toro D, Seiradake E. GPC3-Unc5 receptor complex structure and role in cell migration. Cell. 2022 Oct13;185(21):3931-3949.e26. doi: 10.1016/j.cell.2022.09.025. PMID: 36240740;PMCID: PMC9596381.
3.Qin L, Wang J, Cheng F, Cheng J, Zhang H, Zheng H, Liu Y, Liang Z, Wang B, Li
C, Wang H, Ju Y, Tian H, Meng S. GPC3 and PEG10 peptides associated with
placental gp96 elicit specific T cell immunity against hepatocellular carcinoma.
Cancer Immunol Immunother. 2023 Dec;72(12):4337-4354. doi:10.1007/s00262-023-03569-2. Epub 2023 Nov 6. PMID: 37932427; PMCID: PMC10700408.